Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Ontario, Canada. The company was founded in 2014 and focuses on developing targeted alpha therapeutics for the treatment of cancer. Fusion's proprietary technology platform, known as Fast-Clear™, is designed to safely deliver highly potent alpha-emitting payloads to cancerous tumors while minimizing damage to healthy tissues. The company aims to develop more effective treatments with fewer side effects for patients with cancer.
Fusion Pharmaceuticals went public on June 18, 2020, and raised $212 million through its initial public offering (IPO). The company priced its IPO at $17 per share, higher than the expected range of $14 to $16 per share. The stock began trading on the Nasdaq Global Select Market under the ticker symbol "FUSN."
As of 2021, Fusion is advancing its lead product candidate, FPI-1434, into Phase 1 clinical trials for the treatment of solid tumors. The company has also entered into partnerships with various pharmaceutical companies, including AstraZeneca and Merck, to develop alpha-emitting radiopharmaceuticals for the treatment of cancer.
Fusion Pharmaceuticals has received several awards and recognitions for its innovative technology platform and its potential to advance cancer treatment. In 2020, the company was named one of the "50 Best Small Workplaces" by Great Place to Work® and Fortune magazine. Fusion was also recognized as a finalist in the "Startup of the Year" category at the 2020 Canada Innovation Awards.